{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:28:06Z","timestamp":1794317286725,"version":"4.9.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016242","name":"Barnekreftforeningen","doi-asserted-by":"publisher","award":["230004"],"award-info":[{"award-number":["230004"]}],"id":[{"id":"10.13039\/501100016242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2021_EKFK_01"],"award-info":[{"award-number":["2021_EKFK_01"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["326300"],"award-info":[{"award-number":["326300"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["262652"],"award-info":[{"award-number":["262652"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["261936"],"award-info":[{"award-number":["261936"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["301268"],"award-info":[{"award-number":["301268"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["310531"],"award-info":[{"award-number":["310531"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["326811"],"award-info":[{"award-number":["326811"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["284983"],"award-info":[{"award-number":["284983"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021372","name":"Hector Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021372","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["510821390"],"award-info":[{"award-number":["510821390"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KO5055-2-1"],"award-info":[{"award-number":["KO5055-2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB-TRR 338\/1 2021\\u2013452881907"],"award-info":[{"award-number":["SFB-TRR 338\/1 2021\\u2013452881907"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["756017"],"award-info":[{"award-number":["756017"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["101100460"],"award-info":[{"award-number":["101100460"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005036","name":"Universitetet i Bergen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["2022009"],"award-info":[{"award-number":["2022009"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["2024080"],"award-info":[{"award-number":["2024080"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002745","name":"Bayerische Forschungsstiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002745","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","award":["2022.051.1"],"award-info":[{"award-number":["2022.051.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["182524"],"award-info":[{"award-number":["182524"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["2017064"],"award-info":[{"award-number":["2017064"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["2017072"],"award-info":[{"award-number":["2017072"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["2018012"],"award-info":[{"award-number":["2018012"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["KSP-2021"],"award-info":[{"award-number":["KSP-2021"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["2019096"],"award-info":[{"award-number":["2019096"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["801133"],"award-info":[{"award-number":["801133"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["EURONANOMED-3 NAN-4-TUM"],"award-info":[{"award-number":["EURONANOMED-3 NAN-4-TUM"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010138","name":"Fritz-Bender-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010138","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005632","name":"Narodowe Centrum Bada\u0144 i Rozwoju","doi-asserted-by":"publisher","award":["0056\/2019"],"award-info":[{"award-number":["0056\/2019"]}],"id":[{"id":"10.13039\/501100005632","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["208012"],"award-info":[{"award-number":["208012"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["223171"],"award-info":[{"award-number":["223171"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["2018012"],"award-info":[{"award-number":["2018012"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.xcrm.2024.101572","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T10:42:51Z","timestamp":1715769771000},"page":"101572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia"],"prefix":"10.1016","volume":"5","author":[{"given":"Benjamin","family":"Caulier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8558-9399","authenticated-orcid":false,"given":"Sandy","family":"Joaquina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Gelebart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara Hel\u00e9n","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Kaveh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luka","family":"Tandaric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Wernhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niveditha Umesh","family":"Katyayini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Wogsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May Eriksen","family":"Gjerstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yngvar","family":"Fl\u00f8isand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Kvalheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Marr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kobold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorrit M.","family":"Enserink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn Tore","family":"Gjertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmet","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Else Marit","family":"Inderberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"W\u00e4lchli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101572_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101572_bib2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101572_bib3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101572_bib4","article-title":"Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats","volume":"8","author":"Williams","year":"2019","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.xcrm.2024.101572_bib5","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1080\/10428194.2017.1344905","article-title":"The emerging role of immune checkpoint based approaches in AML and MDS","volume":"59","author":"Boddu","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.xcrm.2024.101572_bib6","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/onc.2010.511","article-title":"Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells","volume":"30","author":"Majeti","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2024.101572_bib7","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101572_bib8","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/ajh.25214","article-title":"Acute myeloid leukemia: 2019 update on risk-stratification and management","volume":"93","author":"Estey","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.xcrm.2024.101572_bib9","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1182\/blood-2016-10-696054","article-title":"Biology and relevance of human acute myeloid leukemia stem cells","volume":"129","author":"Thomas","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101572_bib10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of Relapsed Acute Myeloid Leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.xcrm.2024.101572_bib11","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T\u00a0cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101572_bib12","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T\u00a0cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101572_bib13","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101572_bib14","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and efficacy of second generation CAR T\u00a0cell against the LeY antigen in acute myeloid leukemia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2024.101572_bib15","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101572_bib16","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor Antigen Escape from CAR T-cell Therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2024.101572_bib17","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrm1736","article-title":"Tetraspanin functions and associated microdomains","volume":"6","author":"Hemler","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2024.101572_bib18","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ccr.2012.03.040","article-title":"Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals","volume":"21","author":"Lapalombella","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2024.101572_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249531","article-title":"CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies","volume":"21","author":"Bobrowicz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2024.101572_bib20","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.4049\/jimmunol.2000768","article-title":"Spacer Length Modification Facilitates Discrimination between Normal and Neoplastic Cells and Provides Clinically Relevant CD37 CAR T Cells","volume":"206","author":"Okuno","year":"2021","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2024.101572_bib21","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3389\/fimmu.2018.01185","article-title":"Antitumor Immunity Is Controlled by Tetraspanin Proteins","volume":"9","author":"Schaper","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2024.101572_bib22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00418-015-1326-2","article-title":"Multispectral imaging reveals the tissue distribution of tetraspanins in human lymphoid organs","volume":"144","author":"de Winde","year":"2015","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.xcrm.2024.101572_bib23","doi-asserted-by":"crossref","first-page":"905","DOI":"10.4049\/jimmunol.140.3.905","article-title":"The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein","volume":"140","author":"Schwartz-Albiez","year":"1988","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2024.101572_bib24","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1158\/1535-7163.MCT-15-0067","article-title":"AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B\/T-Cell Malignancies and AML: A New Role for CD37 in AML","volume":"14","author":"Pereira","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.xcrm.2024.101572_bib25","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.3389\/fimmu.2018.01606","article-title":"Expression and Function of Tetraspanins and Their Interacting Partners in B Cells","volume":"9","author":"Zou","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2024.101572_bib26","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/sj.leu.2403822","article-title":"Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation","volume":"19","author":"Barrena","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101572_bib27","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00277-022-04785-z","article-title":"CD37 expression in follicular lymphoma","volume":"101","author":"Yoshimura","year":"2022","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.xcrm.2024.101572_bib28","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1182\/blood-2016-05-715094","article-title":"Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma","volume":"128","author":"Xu-Monette","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101572_bib29","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1182\/blood-2016-11-748137","article-title":"Staining the target: CD37 expression in lymphomas","volume":"128","author":"Bertoni","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101572_bib30","article-title":"CD37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia","volume":"40","author":"Zhang","year":"2020","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.xcrm.2024.101572_bib31","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","article-title":"Anti-CD37 chimeric antigen receptor T\u00a0cells are active against B- and T-cell lymphomas","volume":"132","author":"Scarfo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101572_bib32","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1182\/bloodadvances.2018029678","article-title":"Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma","volume":"3","author":"Koksal","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.xcrm.2024.101572_bib33","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3390\/cancers13050981","article-title":"Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma","volume":"13","author":"Golubovskaya","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2024.101572_bib34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/bjh.13099","article-title":"Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR therapeutic protein, for relapsed or refractory NHL patients","volume":"168","author":"Pagel","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.xcrm.2024.101572_bib35","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2013-05-505685","article-title":"A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies","volume":"122","author":"Deckert","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101572_bib36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-3083.1985.tb01422.x","article-title":"Characterization of two murine monoclonal antibodies reactive with human B cells. Their use in a high-yield, high-purity method for isolation of B cells and utilization of such cells in an assay for B-cell stimulating factor","volume":"21","author":"Smeland","year":"1985","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.xcrm.2024.101572_bib37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41467-022-35624-4","article-title":"Early response evaluation by single cell signaling profiling in acute myeloid leukemia","volume":"14","author":"Tislevoll","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101572_bib38","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1200\/JCO.2009.23.4732","article-title":"Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group","volume":"28","author":"Haferlach","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101572_bib39","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1186\/1471-2105-10-422","article-title":"Quantitative comparison of microarray experiments with published leukemia related gene expression signatures","volume":"10","author":"Klein","year":"2009","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.xcrm.2024.101572_bib40","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/leu.2015.95","article-title":"NFATc1 as a therapeutic target in FLT3-ITD-positive AML","volume":"29","author":"Metzelder","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101572_bib41","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood-2008-09-179895","article-title":"Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome","volume":"113","author":"Wouters","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101572_bib42","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood-2013-02-485771","article-title":"Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients","volume":"123","author":"Rapin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101572_bib43","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101572_bib44","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood-2003-05-1524","article-title":"Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region","volume":"102","author":"Heemskerk","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101572_bib45","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jim.2016.01.007","article-title":"Assessment of costimulation and coinhibition in a triple parameter T\u00a0cell reporter line: Simultaneous measurement of NF-kappaB, NFAT and AP-1","volume":"430","author":"Jutz","year":"2016","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.xcrm.2024.101572_bib46","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41467-022-28243-6","article-title":"CAR T\u00a0cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells","volume":"13","author":"Hebbar","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101572_bib47","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/leu.2010.119","article-title":"Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification","volume":"24","author":"van den Ancker","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101572_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.949423","article-title":"Divide and Conquer: Phenotypic and Temporal Heterogeneity Within CD8+ T Cell Responses","volume":"13","author":"Richard","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2024.101572_bib49","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1182\/blood-2021-145102","article-title":"Safety and Efficacy of CD37-Targeting Naratuximab Emtansine PLUS Rituximab in Diffuse Large B-Cell Lymphoma and Other NON-Hodgkin\u2019S B-Cell Lymphomas - a Phase 2 Study","volume":"138","author":"Levy","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101572_bib50","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s10637-018-0570-4","article-title":"Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study","volume":"36","author":"Stathis","year":"2018","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.xcrm.2024.101572_bib51","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1182\/bloodadvances.2018029678","article-title":"Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma","volume":"3","author":"K\u00f6ksal","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2024.101572_bib52","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1038\/s41467-022-33138-7","article-title":"Fatty acid metabolism in aggressive B-cell lymphoma is inhibited by tetraspanin CD37","volume":"13","author":"Peeters","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101572_bib53","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1182\/blood.2020008551","article-title":"Very long chain fatty acid metabolism is required in acute myeloid leukemia","volume":"137","author":"Tcheng","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101572_bib54","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101572_bib55","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","article-title":"A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia","volume":"28","author":"Zeng","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101572_bib56","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1016\/j.ymthe.2022.07.006","article-title":"Targeting glycans for CAR therapy: The advent of sweet CARs","volume":"30","author":"Raglow","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2024.101572_bib57","series-title":"The EBMT\/EHA CAR-T Cell Handbook","first-page":"147","article-title":"Management of Hypogammaglobulinaemia and B-Cell Aplasia","author":"Topp","year":"2022"},{"key":"10.1016\/j.xcrm.2024.101572_bib58","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood.2020009192","article-title":"Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia","volume":"138","author":"Jetani","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101572_bib59","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T\u00a0cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101572_bib60","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jaci.2022.07.018","article-title":"Expression and regulation of Siglec-6 (CD327) on human mast cells and basophils","volume":"151","author":"Smiljkovic","year":"2023","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.xcrm.2024.101572_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000481","article-title":"Attenuated T\u00a0cell responses to a high-potency ligand in\u00a0vivo","volume":"8","author":"Corse","year":"2010","journal-title":"PLoS Biol."},{"key":"10.1016\/j.xcrm.2024.101572_bib62","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T\u00a0cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101572_bib63","first-page":"629","article-title":"Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T\u00a0cell persistence in patients","volume":"2","author":"Biasco","year":"2021","journal-title":"Nat. Can. (Ott.)"},{"key":"10.1016\/j.xcrm.2024.101572_bib64","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ymthe.2022.09.003","article-title":"Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T\u00a0cells for T\u00a0cell malignancies","volume":"31","author":"Watanabe","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2024.101572_bib65","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101572_bib66","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41586-023-06496-5","article-title":"Epitope editing enables targeted immunotherapy of acute myeloid leukaemia","volume":"621","author":"Casirati","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101572_bib76","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nprot.2015.020","article-title":"Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm","volume":"10","author":"Zunder","year":"2015","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2024.101572_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-019-0415-5","article-title":"diffcyt: Differential discovery in high-dimensional cytometry via high-resolution clustering","volume":"2","author":"Weber","year":"2019","journal-title":"Commun. Biol."},{"key":"10.1016\/j.xcrm.2024.101572_bib74","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/cyto.a.22625","article-title":"FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data","volume":"87","author":"Van Gassen","year":"2015","journal-title":"Cytometry A."},{"key":"10.1016\/j.xcrm.2024.101572_bib67","unstructured":"Whole transcriptome RNA sequencing on bone marrow and peripheral blood samples from patients with acute myeloid leukemia at diagnosis or relapse. - EGA European Genome-Phenome Archive https:\/\/ega-archive.org\/datasets\/EGAD00001004187."},{"key":"10.1016\/j.xcrm.2024.101572_bib68","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13059-017-1382-0","article-title":"SCANPY: large-scale single-cell gene expression data analysis","volume":"19","author":"Wolf","year":"2018","journal-title":"Genome Biol"},{"key":"10.1016\/j.xcrm.2024.101572_bib69","article-title":"anndata: Annotated data","author":"Virshup","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.xcrm.2024.101572_bib70","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13059-016-0947-7","article-title":"Pooling across cells to normalize single-cell RNA sequencing data with many zero counts","volume":"17","author":"L Lun","year":"2016","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2024.101572_bib71","first-page":"2122","article-title":"A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor","volume":"5","author":"Lun","year":"2016","journal-title":"F1000Res."},{"key":"10.1016\/j.xcrm.2024.101572_bib72","doi-asserted-by":"crossref","first-page":"14049","DOI":"10.1038\/ncomms14049","article-title":"Massively parallel digital transcriptional profiling of single cells","volume":"8","author":"Zheng","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101572_bib73","article-title":"UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction","author":"McInnes","year":"2020","journal-title":"arXiv"},{"key":"10.1016\/j.xcrm.2024.101572_bib75","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nmeth.4149","article-title":"Characterizing cell subsets using marker enrichment modeling","volume":"14","author":"Diggins","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2024.101572_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02367","article-title":"Minimizing Batch Effects in Mass Cytometry Data","volume":"10","author":"Schuyler","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2024.101572_bib82","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1472-6750-10-81","article-title":"Improved Tet-responsive promoters with minimized background expression","volume":"10","author":"Loew","year":"2010","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.xcrm.2024.101572_bib83","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nbt.3235","article-title":"Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains","volume":"33","author":"Shi","year":"2015","journal-title":"Nat. Biotechnol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124002647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124002647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:16:03Z","timestamp":1778919363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124002647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2666379124002647"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101572","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101572","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101572"}}